Eicosanoids and the stomach

Prostaglandins and Other Lipid Mediators

Volumn 61, Issue 3-4, 2000, Pages 105-124

  Atay, Songul ^a   Tarnawski, Andrzej S ^a   Dubois, Andre ^b  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

Apoptosis; Eicosanoids; Emptying; Gastroprotection; Motility; Mucosal defense; Secretion; Stomach

Indexed keywords

7 CHLORO 4 HYDROXY 2 (4 METHOXYBENZYL) 3 METHYL 5 PROPYLBENZOFURAN; ACETYLSALICYLIC ACID; ANTIULCER AGENT; CYCLOOXYGENASE 2; ICOSANOID; INDOMETACIN; LEUKOTRIENE; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN;

APOPTOSIS; GASTRITIS; HUMAN; IMMUNOMODULATION; MITOGENESIS; NONHUMAN; REVIEW; STOMACH; STOMACH EMPTYING; STOMACH EROSION; STOMACH MOTILITY; STOMACH MUCOSA; STOMACH PROTECTION; STOMACH SECRETION; STOMACH ULCER; ULCER HEALING;

ANIMALS; EICOSANOIDS; GASTRIC MUCOSA; HUMANS; STOMACH;

EID: 0034040062     PISSN: 00906980     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-6980(00)00067-8     Document Type: Review

References (153)

1. Eberhart C.E., DuBois R.N. Eicosanoids and the gastrointestinal tract. Gastroenterology. 109:1995;285-301.
2. Smith W.L., Marnett L.J. Prostaglandin endoperoxide synthase structure and catalysis . Biochim Biophys Acta. 1083:1991;1-17.
3. Capdevila J.H., Wei S., Yan J., et al. Cytochrome P-450 arachidonic acid epoxygenase regulatory control of the renal epoxygenase by dietary salt loading . J Biol Chem. 267:1992;21720-21726.
4. Lewis R.A., Austen K.F., Soberman R.J. Leukotrienes and other products of the 5-lipoxygenase pathway biochemistry and relation to pathobiology in human diseases . N Engl J Med. 323:1990;645-655.
5. Marnett L. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res. 52:1992;5575-5589.
6. Salvemini D., Misko T.P., Masferer J.L., et al. Nitric oxide activates cyclooxygenase enzymes. Proc Natl Acad Sci USA. 90:1993;7240-7244.
7. Salvemini D., Seibert K., Masferer J.L., et al. Nitric oxide and the cyclooxygenase pathway. Adv Prostaglandin Thromboxane Leukotriene Res. 23:1995;491-493.
8. Robert A., Nezamis J.E., Phillips J.P. Inhibition of gastric secretion by prostaglandin. Am Dig Dis. 12:1967;1073-1076.
9. 1 on gastric secretion and ulcer formation in the rat. Gastroenterology. 55:1968;481-487.
10. Dajani E.Z., Callison D.A., Bianch R.G., Driskill D.R. Gastric antisecretory effects of E prostaglandins in rhesus monkeys. Am J Dig Dis. 21:1976;1020-1028.
11. 2 analog on gastric emptying and secretion in rhesus monkeys. J Pharmacol Exp Ther. 212:1980;491-495.
12. 2a on human gastric function. Gut. 16:1976;272-276.
13. Shea-Donohue P.T., Myers L., Castell D.O., Dubois A. Effect of prostacyclin on gastric emptying and secretion in rhesus monkeys. Gastroenterol. 78:1980;1476-1479.
14. 2a on gastric parietal and non-parietal secretion. Dig Dis Sci. 27:1982;17-22.
15. Whittle B.J.R., Vane J.R. Prostanoids as regulators of gastrointestinal function. Johnson L.R., Christiansen I., Jackson M.I., Jacobson E.D., Walsh J.H. Physiology of the gastrointestinal tract. 1987;143-180 Raven, New York.
16. 2a on gastric parietal and non-parietal secretion. Dig Dis Sci. 27:1982;17-22.
17. Ferreira S.H., Vane J.R. Prostaglandins their disappearance from and release into the circulation . Nature. 216:1967;868-873.
18. Susuki H., Kuriyama H. Electrical and mechanical properties of longitudinal smooth muscle of the guinea pig ileum. Jpn J Physiol. 25:1975;759-773.
19. Sanders K.M., Northrup T.E. Prostaglandin synthesis by microsomes of circular and longitudinal gastrointestinal muscles. Am J Physiol. 244:1983;G442-G448.
20. Sanders K.M. Role of prostaglandins in regulating gastric motility. Am J Physiol. 247:1984;G117-G126.
21. 2a analog on gastric emptying and secretion in rhesus monkeys. J Pharmacol Exp Ther. 219:1981;287-289.
22. Dubois A., Conklin J.J. Prostaglandins and gastric emptying. Adv Prostaglandin Thromboxane Leukotriene Res. 17:1987;370-372.
23. Tarnawski A., Hollander D. Cytoprotection of gastric and duodenal mucosa. The Royal Society of Medicine. Curr Med Lit Gastroenterol. 6:1987;3-9.
24. Szabo S. Mechanisms of mucosal protection. In: Hollander D, Tarnawski A, editors. Gastric cytoprotection: a clinician's guide. 1989. pp. 49-60.
25. Wallace J.L., Granger D.N. The cellular and molecular basis of gastric mucosal defense. FASEB J. 10:1996;731-740.
26. Allen A., Flemstrom G., Garner A., Kivilaakso E. Gastroduodenal mucosal protection. Physiol Rev. 73:1993;823-857.
27. Maricic N., Ehrlich K., Respondek M., Peskar B.M. Rat gastric ischemia/reperfusion injury role of nitric oxide and relation to COX-1 and COX-2 . Gastroenterology. 114:1998;A216.
28. Tarnawski A., Erickson R.A. Sucralfate, 24 years later current concepts of its protective and therapeutic actions . Europ J Gastroenterol Hepatol. 3:1991;795-810.
29. 2 in dogs. Role of gastric acid secretion. Prostaglandins. 34:1987;623-632.
30. Redfern J.S., Feldman M. Role of endogenous prostaglandins in preventing gastrointestinal ulceration induction of ulcers by antibodies to prostaglandins . Gastroenterology. 96:1989;596-605.
31. Redfern J.S., Lee E., Feldman M. Effect of immunization with prostaglandin metabolites on gastrointestinal ulceration. Am J Physiol. 255:1988;G723-G730.
32. Tarnawski A., Arakawa T. Preventing GI damage with cytoprotective drugs. Contemp Int Med. 4:1992;95-109.
33. Edwards M.J. Apoptosis, the heat shock response, hyperthermia, birth defects, disease and cancer. Where are the common links? Cell Stress Chaperones. 3:1998;213-220.
34. 2 inhibitors on proliferation and apoptosis of murine intestinal cells. J Surg Res. 84:1999;51-56.
35. Chan T.A., Morin P.J., Vogelstein B., Kinzler K.W. Mechanisms underlying nonsteroidal anti-inflammatory drug mediated apoptosis. Proc Natl Acad Sci USA. 95:1998;681-686.
36. Erickson B.A., Longo W.E., Panesar N., Mazusi J.E., Kaminski D.L. The effect of selective cyclooxygenase inhibitors on intestinal epithelial cell mitogenesis. J Surg Res. 81:1999;101-107.
37. Sawaoka H., Kawano S., Tsuji S., Tsujii M., Murata H., Hori M. Effects of NSAIDs on proliferation of gastric cancer cells in vitro possible implication of cyclooxygenase-2 in cancer development . J Clin Gastroenterol. 27:(suppl. 1):1998;S47-S52.
38. Kusuhara H., Matsuyuki H., Matsura M., Imayoshi T., Okumoto T., Matsui H. Induction of apoptotic DNA fragmentation by nonsteroidal anti-inflammatory drugs in cultured rat gastric mucosal cells. Eur J Pharmacol. 360:1998;273-280.
39. Sawaoka H., Kawano S., Tsuji S., et al. Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am J Physiol. 274:1998;G1061-G1067.
40. Slomiany B.L., Piotrowski J., Slomiany A. Induction of TNF-α and apoptosis in gastric mucosal injury by indomethacin effect of omeprazole and ebrotidine . Scand J Gastroenterol. 32:1997;638-642.
41. Zhang X., Morham S.G., Langenbach R., Young D.A. Malignant transformation and antineoplastic actions of nonsteroidal anti-inflammatory drugs on cyclooxygenase-null embryo fibroblasts. J Exp Med. 190:1999;451-459.
42. 2. J Biol Chem. 274:1999;17042-17048.
43. Clay C.E., Namen A.M., Atsumi Gi, et al. Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells. Carcinogenesis. 20:1999;1905-1911.
44. Lim J.T., Piazza G.A., Han E.K., et al. Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines. Biochem Pharmacol. 58:1999;1097-1107.
45. Robert A, Nezamis JE, Lancaster C, Hancher AJ. Protection by prostaglandins in rat. Prevention of gastric necrosis produced by alcohol, HCl, hypertonic NaCl, and thermal injury. Gastroenterology 1997;77:433-43.
46. Robert A. Cytoprotection: historical perspective. In: Hollander D, Tarnawski A, editors. Gastric cytoprotection: a clinician's guide. 1989. pp. 3-12.
47. McCarthy D.M. Mechanism of mucosal injury and healing the role of nonsteroidal anti-inflammatory drugs . Scand J Gastroenterol. 30:(suppl. 208):1995;24-29.
48. Graham D.Y., Agrawal N.M., Rot S.H. Prevention of NSAID-induced gastric ulcer with Misoprostol multicenter, double-blind, placebo-controlled trial . Lancet. 2:1988;1277.
49. Tarnawski A., Stachura J., Ivey K.J., Mach T., Bogdal J., Klimczyk B. Ethanol induced duodenal lesions in man. Protective effect of prostaglandin. Prostaglandins. 21:(suppl.):1981;147-153.
50. Tarnawski A., Stachura J., Hollander D., Sarfeh I.J., Bogdal J. Cellular aspects of alcohol-induced injury and prostaglandin protection of the human gastric mucosa. Focus on the mucosal microvessels. J Clin Gastroenterol. 10:(suppl. 1):1988;S35-S45.
51. Tarnawski A., Brzozowski T., Sarfeh I.J., et al. Prostaglandin protection of human isolated gastric glands against indomethacin and ethanol injury evidence for direct cellular action of prostaglandin . J Clin Invest. 81:1988;1081.
52. 2 in human gastric ulcers. Gastroenterol Jpn. 17:1982;21-24.
53. 2 in gastric mucosa of patients with alcoholic cirrhosis and portal hypertension. Gastroenterology. 93:1987;135-140.
54. 2 in gastric ulcers induced by nonsteroidal anti-inflammatory compounds (NSAC). Gastroenterol Jpn. 16:1981;600-603.
55. Kobayashi K., Nakamura H., Arakawa T. Secretagogues stimulate prostaglandin synthesis and inhibit mucosal damage induced by a necrotizing agent in rat gastric mucosa. J Clin Gastroenterol. 10:(suppl. 1):1988;S133-S139.
56. Robert A., Nezamis J.E., Lancaster C., Davis J.P., Field S.O., Hanchar A.J. Mild irritants prevent gastric necrosis through "adaptive cytoprotection" mediated by prostaglandins. Am J Physiol. 245:1983;G113-G121.
57. Arakawa T., Nakamura A., Fukuda T., Higuchi K., Nakamura H., Kobayashi K. In vitro adaptive cytoprotection in gastric cells isolated from rat stomach. J Clin Gastroenterol. 12:(suppl. 1):1990;S32-S38.
58. Arakawa T., Fukuda T., Kobayashi K.J., Kobayashi K., Tarnawski A. Prostaglandin-induced protection of cultured rat gastric cells against ethanol is inhibited by a microtubule inhibitor. Digestion. 57:1996;4-46.
59. Nakamura K., Rokutan K., Marui N., Aoike A., Kawai K. Induction of heat shock proteins and their implication in protection against ethanol induced damage in cultured guinea pig gastric mucosal cells. Gastroenterology. 101:1991;161-166.
60. 2. Mol Cell Biol. 12:1992;1528-1534.
61. Jin M., Otaka M., Okuyama A., et al. Association of 72-kDa heat shock protein expression with adaptation to aspirin in rat gastric mucosa. Dig Dis Sci. 44:1999;1401-1407.
62. Amici C., Sistonen L., Santoro M.G., Morimoto R.I. Antiproliferative prostaglandins activate heat shock transcription factor. Proc Natl Acad Sci USA. 89:1992;6227-6231.
63. Santoro M.G. Heat shock proteins and virus replication hsp70s as mediators of the antiviral effects of prostaglandins . Experientia. 50:1994;1039-1047.
64. Sharma H.S., Westman J. Prostaglandins modulate constitutive isoform of heat shock protein (72 kDa) response after trauma to the rat spinal cord. Acta Neurochir Suppl (Wien). 70:1997;134-137.
65. Ethridge R.T., Hellmich M.R., DuBois R.N., Evers B.M. Inhibition of heat-shock protein 70 induction in intestinal cells overexpressing cyclooxygenase 2. Gastroenterology. 115:1998;144-163.
66. 2 alpha. J Anim Sci. 73:1995;1789-1792.
67. Scheiman J.M. Pathogenesis of gastroduodenal injury due to nonsteroidal anti-inflammatory drugs implications for prevention and therapy . Semin Arthritis Rheum. 21:1992;201-210.
68. Sarosiek J., Mizuta K., Slomiany A., et al. Effects of acetylsalicylic acid on gastric mucin viscosity, permeability to hydrogen ion, and susceptibility to pepsin. Biochem Pharmacol. 35:1986;4291-4295.
69. 2 output in human subjects. Ann Intern Med. 16:1987;368-371.
70. Levi S., Goodlad R.A., Lee C.Y., et al. Inhibitory effect of nonsteroidal anti-inflammatory drugs on mucosal cell proliferation associated with gastric ulcer healing. Lancet. 2:1990;840-843.
71. Scheiman J.M. NSAIDs, gastrointestinal injury, and cytoprotection. Gastroenterology Clin North Am. 25:1996;279-298.
72. Feldman M., Colturi T.J. Effect of indomethacin on gastric acid and bicarbonate secretion in humans. Gastroenterology. 87:1984;1339-1343.
73. Cohen M.M. Role of endogenous prostaglandins in gastric secretion and mucosal defense. Clin Invest Med. 10:1987;226-231.
74. Taylor S.D., Soudah H.C., Chey W.Y., et al. Prostaglandins mediate the inhibition of human gastric acid secretion produced by intraduodenal acidification and secretin but not intraduodenal fat. Gastroenterology. 107:1994;1680-1685.
75. Kitahora T., Guth P.H. Effect of aspirin plus hydrochloric acid on the gastric mucosal microcirculation. Gastroenterology. 93:1987;810-817.
76. Wallace J.L., Arfors K.E., McKnight G.W. A monoclonal antibody against the CD18 leukocyte adhesion molecule prevents indomethacin induced gastric damage in the rabbit. Gastroenterology. 100:1991;878-883.
77. Wallace J.L., Keenan C.M., Granger D.N. Gastric ulceration induced by nonsteroidal anti-inflammatory drugs in a neutrophil-dependent process. Am J Physiol. 259:1990;G462-G467.
78. Wallace J.L. Mechanisms of nonsteroidal anti-inflammatory drug induced gastrointestinal damage - potential for development of gastrointestinal tract safe NSAIDs. Can J Physiol Pharmacol. 72:1994;1493-1498.
79. Wallace J.L., Keenan C.M., Cucala M., et al. Mechanisms underlying the protective effects of interleukin 1 in experimental nonsteroidal anti-inflammatory drug gastropathy. Gastroenterology. 102:1992;1175-1176.
80. Wallace J.L., Reuter B., Cicala C., et al. Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. Gastroenterology. 107:1994;173-179.
81. Walt R.P. Misoprostol for the treatment of peptic ulcer and anti-inflammatory drug induced gastroduodenal ulceration. N Engl J Med. 327:1992;1575-1580.
82. Graham D.Y., Agrawal N.M., Roth S.H. Prevention of NSAID-induced gastric ulcer with Misoprostol multicenter, double-blind, placebo controlled trial . Lancet. 2:1988;1277-1280.
83. Soll A.H., Weinstein W.M., Kurata J., et al. Nonsteroidal anti-inflammatory drugs and peptic ulcer disease. Ann Intern Med. 114:1991;307-319.
84. Elliott S.L., Yeomans N.D., Buchanan R.R.C., et al. Efficacy of 12 months' Misoprostol as prophylaxis against NSAID-induced gastric ulcers. Scand J Rheumatol. 23:1994;171-176.
85. Silverstein F.S., Geis G.S., Struthers B.J., et al. NSAIDs and gastrointestinal injury clinical outcome, the MUCOSA trial . Gastroenterology. 106:1994;A180.
86. Ballif B.A., Mincek N.V., Barratt J.T., Wilson M.L., Simmons D.L. Interaction of cyclooxygenases with an apoptosis and autoimmunity associated protein. Proc Natl Acad Sci USA. 93:1996;5544-5549.
87. Meade E.A., Smith W.L., DeWitt D.L. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 268:1993;6610-6614.
88. O'Neill G.P., Ford-Huchinson A.W. Expression of mRNA for cyclooxygenase 1 and cyclooxygenase 2 in human tissues. FEBS Lett. 350:1993;156-160.
89. Fosslien E. Adverse effects of nonsteroidal anti-inflammatory drugs on the gastrointestinal system. Ann Clin Lab Sci. 28:1998;67-81.
90. Mitchell J.A., Akarasereenont P., Thiemermann C., Flower R.J., Vane J.R. Selectivity of nonsteroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA. 90:1994;11693-11697.
91. th ed. Philadelphia: Saunders, 1998. pp. 343-57.
92. Schmassmann A., Peskar B.M., Stettler C., et al. Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastrointestinal ulcer models in rats. Brit J Pharmacol. 123:1989;795-804.
93. Futaki N.Y., Yoshikawa K., Hamasaka Y., et al. NS-398, a novel nonsteroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. Gen Pharmacol. 24:1993;105-110.
94. Geis G.S. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor what can we expect? J Rheumatol Suppl. 56:1999;31-36.
95. Chan C., Boyce S., Brideau C., et al. Rofecoxib a potent and orally active cyclooxygenase-2 inhibitor . Pharmacological and biochemical profiles. J PET. 290:1999;551-560.
96. Simon L., Lanza F.L., Lipsky P.E., et al. Preliminary study of the safety and efficacy of SC-5863, a novel cyclooxygenase-2 inhibitor. Arthritis & Rheumatism. 41:1998;1591-1602.
97. Laine L., Harper S., Simon T., et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology. 117:1999;776-783.
98. Cryer B., Gottesdiener K., Gertz B., et al. In vivo effects of rofecoxib, a new cyclooxygenase-2 inhibitor, on gastric mucosal prostaglandin and serum thromboxane B2 synthesis in healthy humans. Gastroenterology. 116:1999;A141.
99. Cryer B., Feldman M. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology. 117:1999;17-25.
100. Langman M., Jensen D., Harper S., et al. Lower incidence of clinically evident upper GI perforations, ulcers, and bleeds in patients treated with rofecoxib vs. nonspecific cyclooxygenase inhibitors. Gastroenterology. 116:1999;A232.
101. Goldstein J.L., Agrawal N.M., Silverstein F., et al. Celecoxib is associated with a significantly lower incidence of clinically significant upper gastrointestinal events in osteoarthritis and rheumatoid arthritis patients as compared to NSAIDs. Gastroenterology. 116:1999;A174.
102. Groopman J. "Super aspirin". The New Yorker, June 15, 1998.
103. Mahmud T., Scott D., Bjarnason I. A unifying hypothesis for the mechanism of NSAID related gastrointestinal toxicity. Annals Rheum Dis. 55:1996;211-213.
104. Rainsford K.D., Tsang S., Hunt R.H., et al. Effects of non-steroidal anti-inflammatory drugs on prostaglandin H synthase isoenzyme 2 (cyclo-oxygenase 2) production by porcine gastric mucosa in organ culture. Inflammatopharmacology. 3:1995;299-300.
105. Iseki S. lmmunocytochemical localization of cyclooxygenase-1 and cyclooxygenase-2 in the rat. Histochem J. 27:1995;323-328.
106. Tarnawski A., Wahlstrom K., Gergely H., et al. Expression of cyclooxygenase 1 and 2 (COX-1 and COX-2) in normal gastric mucosa. Effect of antacid (hydrotalcit) treatment. Gastroenterology. 110:1996;A275.
107. Mizuno H., Sakamoto C., Matusda K., et al. Induction of cyclooxygenase-2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology. 112:1997;387-397.
108. Tarnawski A.S., Kidao J., Jaafar S., et al. Expression and localization of cyclooxygenase-2 in normal and ulcerated human gastric mucosa and in cultured human endothelial cells. Gastroenterology. 112:1997;A309.
109. Davies N.M., Sharkey K.A., Asfaha S., et al. Aspirin causes rapid up-regulation of cyclooxygenase-2 expression in the stomach of rats. Aliment Pharmacol Ther. 11:1997;1101-1108.
110. Donnelly M.T., Hull M.A., Jenkins D., et al. Immunohistochemical distribution of constitutive cyclooxygenase (COX-1) and inducible cyclooxygenase (COX-2) in healing and malignant gastric mucosa. Gastroenterology. 112:1997;A10.
111. Zimmermann K.C., Sarbia M., Schror K., et al. Constitutive cyclooxygenase-2 expression in healthy human and rabbit gastric mucosa. Molec Pharmacol. 54:1998;536-540.
112. Kishimoto Y., Wada K., Nakamoto K., et al. Levels of cyclooxygenase 1 and 2 mRNA expression at various stages of acute gastric injury induced by ischemia-reperfusion in rats. Arch Biochem Biophys. 352:1998;153-157.
113. Takahasi S., Shigeta J., Inoue H., et al. Localization of cyclooxygenase-2 and regulation of its mRNA expression in gastric ulcers in rats. Am J Physiol. 275:1998;G137-G145.
114. Wu C.K., Jackson L., Mahida R., et al. Cyclooxygenase (COX) 1 and 2 in human gastric mucosa. Constitutive expression by parietal cells and induction of COX-2 in lamina propria. Gastroenterology. 114:1998;A334.
115. Fu S., Ramanujam K.S., Wong A., Fantry G., et al. Increased expression and cellular localization of inducible nitric oxide synthase and cyclooxygenase 2 in Helicobacter pylori gastritis. Gastroenterology. 116:1999;1319-1329.
116. McCarthy C.J., Crofford L.J., Greenson J., et al. Cyclooxygenase-2 expression in gastric antral mucosa before and after eradication of Helicobacter pylori infection. Am. J. Gastroenterol. 94:1999;1218-1222.
117. Sawaoka H., Kwano S., Tsuji S., et al. Helicobacter pylori infection induced cyclooxygenase-2 expression in human gastric mucosa. Prostaglandins Leukot Essent Fatty Acids. 59:1998;313-316.
118. 2 synthesis in MKN 28 gastric mucosal cells in vitro. J Bio Chem. 273:1998;2860-2863.
119. Sawaoka H., Tsuji S., Tsujii M., et al. Expression of the cyclooxygenase-2 gene in gastric epithelium. J Clin Gastroenterol. 25:(suppl.1):1997;S105-S110.
120. Sasaki E., Pai R., Halter F., et al. Induction of cyclooxygenase-2 in rat gastric epithelial cell line by epiregulin and basic fibroblast growth factor. J Clin Gastroenterol. 27:(suppl. 1):1998;S21-S22.
121. Jones M.K., Sasaki E., Halter F., et al. HGF triggers activation of COX-2 gene in rat gastric epithelial cells action mediated through ERK2 signaling pathway . FASEB J. 13:1999;2186-2195.
122. Netzer P., Halter F., Ma T., et al. Interactions between HGF and COX-2 during gastric epithelial wound healing. Gastroenterology. 116:1999;A332.
123. Ehrlich K., Plate S., Stroff T., et al. Peptidergic and cholinergic neurons and mediators in peptone-induced gastroprotection role of cyclooxygenase-2 . Am J Physiol. 247:1999;G955-G964.
124. Gretzer B., Ehrlich K., Maricic N., et al. Selective cyclo-oxygenase 2 inhibitors and their influence on the protective effect of a mild irritant in the rat stomach. Br J Pharmacol. 123:1998;927-935.
125. Wallace J.L., Bak A., McKnight W.S., et al. Cyclooxygenase 1 contributes to inflammatory responses in rats and mice implications for gastrointestinal toxicity . Gastroenterology. 115:1998;101-109.
126. Lee S.H., Soyoola E., Chanmugam P., et al. Selective expression of mitogen-inducible cyclooxygenase and macrophages stimulated with lipopolysaccharide. J Biol Chem. 267:1992;25934-25938.
127. Karim S.A., Habib S., Levy-Toledano S., et al. Cyclooxygenase 1 and 2 of endothelial cells utilize exogenous or endogenous arachidonic acid for transcellular production of thromboxane. J Biol Chem. 271:1996;12042-12048.
128. Mitchell J.A., Evans T.W. Cyclooxygenase-2 as a therapeutic target. Inflamm Res. 47:(suppl. 2):1998;S88-S92.
129. Tarnawski A, Stachura, Douglas TG, et al. Indomethacin impairs quality of experimental gastric ulcer healing: a quality histologic and ultrastructural analysis. In: Garner A, O'Brian PEJ, editors. Mechanism of injury, protection and repair of the upper gastrointestinal tract. Chester: Wiley & Sons, 1991. pp. 521-31.
130. Schmassmann A., Tarnawski A., Peskar B.M., Varga L., Flogerzi B., Halter F. Influence of acid and angiogenesis on kinetic of gastric ulcer healing in rats interaction with indomethacin . Am J Physiol. 286:1995;G276-G285.
131. Hudson N., Balsitis M., Everitt S., Hawkey C.J. Angiogenesis in gastric ulcers impaired in patients taking nonsteroidal anti-inflammatory drugs . Gut. 37:1995;191-194.
132. Schmassmann A., Peskar B.M., Stettler C., et al. Effects of inhibition of prostaglandin endoperoxide synthases-2 in chronic gastro-intestinal ulcer models in rats. Br J Pharmacol. 123:1998;795-804.
133. Tarnawski A., Hollander D., Stachura J., Gergely H., Krause W.J., Sarfeh I.J. Role of angiogenesis in healing of experimental gastric ulcer. Halter F., Garner A., Tytgat G.N.J. Mechanisms of peptic ulcer healing. 1991;165-171 Kluwer Acad. Publ, Dordrecht/Boston/London.
134. Tarnawski A. Cellular mechanisms of gastric ulcer healing. Domschke W., Konturek S.J. The stomach. 1993;177-192 Spring, Berlin.
135. Tarnawski A., Hollander D., Stachura J., Sarfeh I.J., Gergely H., Krause W.J. Angiogenic response of gastric mucosa to ethanol injury is abolished by indomethacin. Gastroenterology. 96:1989;A505.
136. Tarnawski A., Hollander D., Stachura J., Sheffield M., Gergely H., Krause W.J. Angiogenic response of damaged gastric mucosa a prostaglandin mediated process . Gastroenterology. 98:1990;A136.
137. Hull M.A., Thomson J.L., Hawkey C.J. Expression of cyclooxygenase 1 and 2 by human gastric endothelial cells. Gut. 45:1999;529-536.
138. Jones M.K., Peskar B., Wang H., Levin E., Itani R.M., Sarfeh I.J., Tarnawski A.S. Inhibition of angiogenesis by NSAIDs. Insight into the mechanisms and implications for cancer growth and ulcer healing. Nat Med. 5:1999;1418-1423.
139. Guslandi M. Gastric effects of leukotrienes. Prostaglandins Leukot Med. 26:1987;203-208.
140. Gyomber E., Vattay P., Szabo S., Rainsford K.D. Effect of lipoxygenase inhibitors and leukotriene antagonists on acute and chronic gastric haemorrhagic mucosal lesions in ulcer models in the rat. J Gastroenterol Hepatol. 11:1996;922-927.
141. 4 cause widespread and extensive plasma extravasation in the guinea pig. Naunyn-Schmiedeberg's Arch Pharmacol. 330:1985;136-141.
142. Pihan G., Rogers C., Szabo S. Vascular injury in acute gastric mucosal damage. Mediatory role of leukotrienes. Dig Dis Sci. 33:1988;625-632.
143. Salvati P., Whittle B.J.R. Investigation of the vascular actions of arachidonate lipoxygenase and cyclooxygenase products of the perfused stomach of rat and rabbit. Prostaglandins. 22:1981;141-156.
144. Pendleton R.G., Stavorski J.R. Evidence for differing leukotriene receptors in gastric mucosa. Eur J Pharmacol. 125:1986;297-299.
145. 4 potentiate acid production by isolated rat parietal cells. Gastroenterology. 97:1985;1420-1429.
146. Wallace J.L. Lipid mediators of inflammation in gastric ulcer. Am J Physiol. 258:1990;G1-G11.
147. Rainsford K.D. The effects of 5-lipoxygenase inhibitors and leukotriene antagonists on the development of gastric lesions induced by nonsteroidal anti-inflammatory drugs in mice. Agents Actions. 21:1987;316-319.
148. Rogers C., Pihan G., Raza A., Szabo S. Possible participation of leukotrienes in the pathogenesis of gastric mucosal lesions and vascular injury induced by ethanol, HCl, NaOH, or aspirin in the rat. Effect of eicosapentaenoic acid or a lipoxygenase inhibitor, L-651 392. Gastroenterology. 92:1987;1808-1817.
149. Balaa M.A., Goldgar D.E. Lipoxygenase enzyme inhibitors diminish ethanol damage to the rat stomach. Clin Res. 34:1986;436A.
150. Wallace F.L., McKnight G.W., MacNaughton W.K. Effects of leukotrienes on susceptibility of the rat stomach to damage and investigation of the mechanism of action. Gastroenterology. 8:1990;1178-1186.
151. 4 and prostanoid release relation to ethanol induced injury . Br J Pharmacol. 93:1988;937-943.
152. Rainsford K.D. Mechanisms of gastrointestinal ulceration from nonsteroidal anti-inflammatory drugs a basis for use and development of protective agents . Rainsford K.D., Velo G.P. Side effects of anti-inflammatory drugs 3. 1992;97-114 Kluwer Academic Publisher, Lancaster.
153. Montcalm-Mazzilli E., Shea-Donohue T. Effect of leukotriene D4 on gastric emptying and secretion in rhesus monkeys. J Pharmacol Exp Ther. 262:1992;850-854.